Scalable Cell‐Free Production of Active T7 RNA Polymerase
Biotechnology and Bioengineering · 2025
DOI: 10.1002/bit.28993 ↗At a glance
Journal article in Biotechnology and Bioengineering, 2025. Written by Ryan N Rezvani and 15 co-authors. Institution: Cell-free Protein Synthesis and Microbial Process Development, National Resilience Inc., San Diego, California, USA. Major MEDLINE topics: DNA-Directed RNA Polymerases, SARS-CoV-2, Viral Proteins. Cited 10 times so far (Crossref); 77 references. Funded by: This study was supported by Defense Advanced Research Projects Agency., Defense Advanced Research Projects Agency.
Abstract (original language)
The SARS‐CoV‐2 pandemic highlighted the urgent need for biomanufacturing paradigms that are robust and fast. Here, we demonstrate the rapid process development and scalable cell‐free production of T7 RNA polymerase, a critical component in mRNA vaccine synthesis. We carry out a 1‐L cell‐free gene expression (CFE) reaction that achieves over 90% purity, low endotoxin levels, and enhanced activity relative to commercial T7 RNA polymerase. To achieve this demonstration, we implement rolling circle amplification to circumvent difficulties in DNA template generation, and tune cell‐free reaction conditions, such as temperature, additives, purification tags, and agitation, to boost yields. We achieve production of a similar quality and titer of T7 RNA polymerase over more than four orders of magnitude in reaction volume. This proof of principle positions CFE as a viable solution for decentralized biotherapeutic manufacturing, enhancing preparedness for future public health crises or emergent threats.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Cell-free Protein Synthesis and Microbial Process Development, National Resilience Inc., San Diego, California, USA.
- Department of Bioengineering, Stanford University, Stanford, California, USA.
- Center for Advanced Sensor Technology and Department of Chemical, Biochemical and Environmental Engineering, University of Maryland, Baltimore, Maryland, USA.
- Department of Chemical Engineering and Department of Bioengineering, Stanford University, Stanford, California, USA.
- Robert F. Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York, USA.
- GE HealthCare Technology and Innovation Center, Niskayuna, New York, USA.
ORCID profiles: Weston Kightlinger, Michael C Jewett
Funding
- This study was supported by Defense Advanced Research Projects Agency.
- Defense Advanced Research Projects Agency
Cite
APA
Rezvani, R. N., Aw, R., Chan, W., Satish, K., Chen, H., Lavy, A., Rimal, S., Patel, D. A., Rao, G., Swartz, J. R., DeLisa, M. P., Kvam, E., Karim, A. S., Krüger, A., Kightlinger, W., & Jewett, M. C. (2025). Scalable Cell‐Free Production of Active T7 RNA Polymerase. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28993
Vancouver
Rezvani RN, Aw R, Chan W, Satish K, Chen H, Lavy A, et al. Scalable Cell‐Free Production of Active T7 RNA Polymerase. Biotechnology and Bioengineering. 2025. doi:10.1002/bit.28993
BibTeX
@article{Rezvani2025,
author = {Rezvani, Ryan N and Aw, Rochelle and Chan, Wei and Satish, Krishnathreya and Chen, Han and Lavy, Adi and Rimal, Swechha and Patel, Divyesh A and Rao, Govind and Swartz, James R and DeLisa, Matthew P and Kvam, Erik and Karim, Ashty S and Krüger, Antje and Kightlinger, Weston and Jewett, Michael C},
title = {Scalable Cell‐Free Production of Active T7 RNA Polymerase},
journal = {Biotechnology and Bioengineering},
year = {2025},
doi = {10.1002/bit.28993}
}
EUVIMED